BIOMAT Database Logo BIOMAT Database Logo

Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. 2010

Kenichi Takayasu, and Shigeki Arii, and Iwao Ikai, and Masatoshi Kudo, and Yutaka Matsuyama, and Masamichi Kojiro, and Masatoshi Makuuchi, and
Department of Diagnostic Radiology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

OBJECTIVE Although iodized oil transarterial chemoembolization (TACE) has been found to have survival benefit in the care of patients with unresectable hepatocellular carcinoma, iodized oil infusion chemotherapy without embolization has not been clearly found inferior to or equal to TACE. The purpose of this study was to determine whether one of these therapies is superior to the other or the two are equal in survival benefit and whether embolization with gelatin sponge particles is indispensable to prolonging survival. METHODS A prospective nonrandomized observational cohort study was conducted over 8 years. Among 11,030 patients with unresectable hepatocellular carcinoma, 8,507 underwent TACE, and 2,523 underwent transarterial infusion therapy with an emulsion of iodized oil and an anticancer agent as initial treatment. Patients with extrahepatic metastasis or any previous treatment were excluded. The primary end point was all-cause mortality. To minimize selection bias, propensity score analysis was used to compare the two groups. RESULTS During the follow-up period, 5,044 patients (46%) died. In the analysis of all patients, TACE was associated with a significantly higher survival rate than infusion therapy without embolization (hazard ratio, 0.60; 95% CI, 0.56-0.64; p = 0.0001). The propensity score analysis showed that the hazard ratio for death in the TACE group (n = 1,699 patients) compared with the group who underwent infusion therapy without embolization (n = 1,699) was 0.70 (95% CI, 0.63-0.76; p = 0.0001). The median survival time of the TACE group was 2.74 years, and the 1-, 3-, and 5-year survival rates were 81%, 46%, and 25%. The corresponding values for the group who underwent transarterial infusion therapy without embolization were 1.98 years and 71%, 33%, and 16%. CONCLUSIONS Propensity score analysis showed that in the treatment of patients with unresectable hepatocellular carcinoma, TACE was associated with significantly better overall survival rates than was transarterial infusion therapy without embolization. TACE can be recommended as initial treatment of these patients.

UI MeSH Term Description Entries
D007459 Iodized Oil A preparation of oil that contains covalently bound IODINE. It is commonly used as a RADIOCONTRAST AGENT and as a suspension medium for CHEMOTHERAPEUTIC AGENTS. Oil, Iodized,Iodized Oils,Iodolipol,Oils, Iodized
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009353 Zinostatin An enediyne that alkylates DNA and RNA like MITOMYCIN does, so it is cytotoxic. Neocarzinostatin
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011795 Surveys and Questionnaires Collections of data obtained from voluntary subjects. The information usually takes the form of answers to questions, or suggestions. Community Survey,Nonrespondent,Questionnaire,Questionnaires,Respondent,Survey,Survey Method,Survey Methods,Surveys,Baseline Survey,Community Surveys,Methodology, Survey,Nonrespondents,Questionnaire Design,Randomized Response Technique,Repeated Rounds of Survey,Respondents,Survey Methodology,Baseline Surveys,Design, Questionnaire,Designs, Questionnaire,Methods, Survey,Questionnaire Designs,Questionnaires and Surveys,Randomized Response Techniques,Response Technique, Randomized,Response Techniques, Randomized,Survey, Baseline,Survey, Community,Surveys, Baseline,Surveys, Community,Techniques, Randomized Response
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum

Related Publications

Kenichi Takayasu, and Shigeki Arii, and Iwao Ikai, and Masatoshi Kudo, and Yutaka Matsuyama, and Masamichi Kojiro, and Masatoshi Makuuchi, and
Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis.
February 2011, AJR. American journal of roentgenology,
Kenichi Takayasu, and Shigeki Arii, and Iwao Ikai, and Masatoshi Kudo, and Yutaka Matsuyama, and Masamichi Kojiro, and Masatoshi Makuuchi, and
Transarterial infusion chemotherapy using cisplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.
July 2009, Cardiovascular and interventional radiology,
Kenichi Takayasu, and Shigeki Arii, and Iwao Ikai, and Masatoshi Kudo, and Yutaka Matsuyama, and Masamichi Kojiro, and Masatoshi Makuuchi, and
Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.
March 2012, Japanese journal of clinical oncology,
Kenichi Takayasu, and Shigeki Arii, and Iwao Ikai, and Masatoshi Kudo, and Yutaka Matsuyama, and Masamichi Kojiro, and Masatoshi Makuuchi, and
Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: A propensity score-matching cohort study.
June 2020, JGH open : an open access journal of gastroenterology and hepatology,
Kenichi Takayasu, and Shigeki Arii, and Iwao Ikai, and Masatoshi Kudo, and Yutaka Matsuyama, and Masamichi Kojiro, and Masatoshi Makuuchi, and
Clinical utility of transarterial infusion chemotherapy using cisplatin-lipiodol emulsion for unresectable hepatocellular carcinoma.
November 2012, Anticancer research,
Kenichi Takayasu, and Shigeki Arii, and Iwao Ikai, and Masatoshi Kudo, and Yutaka Matsuyama, and Masamichi Kojiro, and Masatoshi Makuuchi, and
Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma.
November 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver,
Kenichi Takayasu, and Shigeki Arii, and Iwao Ikai, and Masatoshi Kudo, and Yutaka Matsuyama, and Masamichi Kojiro, and Masatoshi Makuuchi, and
Comparison of overall survival in patients with unresectable hepatic metastases with or without transarterial chemoembolization: A Propensity Score Matching Study.
October 2016, Scientific reports,
Kenichi Takayasu, and Shigeki Arii, and Iwao Ikai, and Masatoshi Kudo, and Yutaka Matsuyama, and Masamichi Kojiro, and Masatoshi Makuuchi, and
Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
June 2017, International journal of clinical pharmacology and therapeutics,
Kenichi Takayasu, and Shigeki Arii, and Iwao Ikai, and Masatoshi Kudo, and Yutaka Matsuyama, and Masamichi Kojiro, and Masatoshi Makuuchi, and
Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review.
September 2014, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Kenichi Takayasu, and Shigeki Arii, and Iwao Ikai, and Masatoshi Kudo, and Yutaka Matsuyama, and Masamichi Kojiro, and Masatoshi Makuuchi, and
Survival analysis of 230 patients with unresectable hepatocellular carcinoma treated with bland transarterial embolization.
January 2020, PloS one,
Copied contents to your clipboard!